Skip to main content
Fig. 6 | Respiratory Research

Fig. 6

From: Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial

Fig. 6

Relationship between baseline SABA use and treatment difference (UMEC/VI vs SAL). CI confidence interval, E-RS Evaluating Respiratory Symptoms: COPD, FEV1 forced expiratory volume in 1 s, LS least squares, SABA short-acting β2-agonist, SAC-TDI self-administered computerised Transition Dyspnoea Index, SAL salmeterol, UMEC umeclidinium, VI vilanterol

Back to article page